TANABE PHARMA EUROPE LTD

Figures converted to GBP from EUR at 0.870 per EUR (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -30.6%

  £13,758,909 → £9,544,480

• Cash

  -18.9%

  £2,670,010 → £2,164,334

• Net assets

  -13.3%

  £14,978,185 → £12,987,571

• Employees

  -10%

  50 → 45

• Operating profit

  -14.3%

  £1,244,020 → £1,065,729

• Profit before tax

  -53.7%

  £3,142,217 → £1,454,275

• Wages

  -0.5%

  £5,179,075 → £5,150,644

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. TANABE PHARMA EUROPE LTD 2025-12-01 → present
2. MITSUBISHI TANABE PHARMA EUROPE LTD 2014-06-02 → 2025-12-01
3. MITSUBISHI PHARMA EUROPE LTD 2001-09-13 → 2014-06-02
4. MTP EUROPE LIMITED 2001-03-09 → 2001-09-13
5. DAMSONBRIGHT LIMITED 2001-01-03 → 2001-03-09

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Financial forecasts for profits and cash flows indicate that the company does not expect any significant downturn. The company has no borrowings. However, the company has significant cash balances and has considerably good financial resources with strong net and current assets at year-end and at date of sign off and the stress testing indicate no issues. As a consequence, the directors believe that the company is well-placed to manage its business risks successfully despite the current economic conditions. Accordingly, the directors consider that the company will be able to settle its liabilities as these fall due for a period of twelve months from the date that these accounts are signed and the accounts have been prepared on a going concern basis.”

Group structure

1. TANABE PHARMA EUROPE LTD · parent
   1. Mitsubishi Tanabe Pharma GmbH 100% · Germany · Sales and marketing

Significant events

• “The office lease was terminated on 7th March 2025 at the break option. The commencement of new office lease is 6th May 2025 therefore the relating asset and the liability will be recognised on the commencement date. The new lease agreement was signed on 8th May 2025.”
• “Mitsubishi Chemical Group (MCG) has decided to transfer all shares of our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC), along with all its wholly owned subsidiaries (including MTPE), to Bain Capital. This transfer is scheduled to take place in 2025.”
• “We discontinued the Herbesser business in FY2023 and divested the Argatroban business in FY2024.”
• “Following the divestment of Argatroban, a transitional service agreement was established to support the buyer during the transition period.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

12

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.